Treatment type

Radioligand Therapy

Treatments and trials using Radioligand Therapy, with the same country and access zoom as New Developments.

All New Developments

Radioligand Therapy breakthroughs

All countriesUnited StatesCanadaUnited KingdomJapanChinaAustraliaSwitzerlandEuropean UnionNewestPatient Stories
FDA ApprovedUnited States

New Radiation Treatment for Hormone-Sensitive Metastatic Prostate Cancer

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) — targeted radiation given with hormone-pathway pills for metastatic prostate cancer that still responds to hormone therapy

FDA approval on 31 July 2026 for a new use of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) injection — a radioligand given by IV — in…

This is for adults with metastatic prostate cancer that still responds to hormone-pathway therapy, whose…